Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics. Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.
Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.
Mechanism Rigosertib is a microtubule-destabilizing agent.
References